September 2015 DAIDS Council Approved Concepts

Concepts represent early planning stages for program announcements, request for applications, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to the Opportunities and Announcements portal.

Council approval does not guarantee that a concept will become an initiative.

Table of Contents

FY 2016 Concepts​

FY 2017 Concepts

U.S.-China Biomedical Collaborative Research Program

For the published request for applications, see the December 11, 2015, Guide announcement, U.S.-China Program for Biomedical Collaborative Research (R01).

U.S.-Brazil Biomedical Collaborative Research Program

Request for Applications—pProposed FY 2016 Initiative

Contact: Margarita Ossorio Goldman

Objective:

  • To increase U.S. scientists’ access to infectious disease and immunology research opportunities in Brazil and support U.S. scientists’ funding for collaborative extramural and intramural research projects
  • To stimulate Brazilian cofunding for Brazilian collaborators working with U.S. scientists on shared research priorities and projects
  • To foster, expand, and strengthen long-term U.S.-Brazil basic, clinical, and translational research collaboration

Description: This initiative will support U.S. investigators working with Brazilian colleagues in collaborative research projects. An overall program of cooperation with Brazil, of which this initiative will be a part, also may include separately supported workshops, training, and other jointly developed activities. The focus will be on immunology and infectious diseases, including HIV/AIDS and its comorbidities (additional areas of focus may be added by other participating NIH Institutes/Centers, including National Cancer Institute, Office of AIDS Research, and National Institute of Neurological Disorders and Stroke). Areas of priority interest to NIAID are determined by U.S. scientists and are likely to include HIV/AIDS, malaria, tuberculosis, influenza, neglected tropical diseases, antimicrobial resistance, and the role of immune responses in pathogenesis. Following standard NIH review and award practices, NIAID and the other participating ICs will fund U.S. co-investigators and the Brazil National Council for Scientific and Technological Development (CNPq) will fund the Brazilian co-investigators in each joint research project application.

Limited Interaction Targeted Epidemiology (LITE)

For the published request for applications, see the May 26, 2016, Guide announcement, Limited Interaction Targeted Epidemiology (LITE) to Advance HIV Prevention (UG3/UH3).

Risks of Adolescence and Injury in HIV Susceptibility (RAIS)

For the published request for applications, see the December 4, 2015, Guide announcement, Risk of Adolescence and Injury in HIV Susceptibility (RAIS) (R01).

Prevention Innovation Program (PIP)

For the published request for applications, see the March 29, 2016, Guide announcement, Prevention Innovation Program III (PIP) (R01).

Advancing HIV Therapeutic Vaccine Science

For the published request for applications, see the April 6, 2016, Guide announcement, Advancing HIV Therapeutic Vaccine Science (U01).

NIAID Preclinical Development Support

For the published request for proposals, see the March 10, 2016, solicitation, Preclinical Development Support.

Staged Vaccine Development (SVD)

For the published broad agency announcement, see the March 11, 2016, solicitation, Staged Vaccine Development.

B Cell Immunology Program for HIV-1 Vaccine Development (BCIP)

For the published request for applications, see the October 21, 2015, Guide announcement, B Cell Immunology Program for HIV-1 Vaccine Development (BCIP).

NHP Cellular Immunology Laboratory for AIDS Vaccine Research and Development

For the published request for proposals, see the April 15, 2016, solicitation, Nonhuman Primate Core Cellular Immunology Laboratory for AIDS Vaccine Research and Development.

Characterization of Mycobacterial-Induced Immunity in HIV-Infected and Uninfected Individuals

For the published program announcement with special receipt, referral and/or review considerations, see the September 30, 2015, Guide announcement, Characterization of Mycobacterial Induced Immunity in HIV-Infected and Uninfected Individuals (R21).

​​​​​​

Content last reviewed on May 23, 2016